Are US cardiologists ADAPTABLE to considering low-dose aspirin for secondary prevention?
Giovanna Liuzzo and Carlo Patrono Department of Cardiovascular and Pulmonary Sciences, Fondazione Policlinico Gemelli-IRCCS, Catholic University School of Medicine, Largo A. Gemelli 8, 00168, Rome, Italy; and Department of Pharmacology, Fondazione Policlinico Gemelli-IRCCS, Catholic University School of Medicine, Largo F. Vito 1, 00168, Rome, Italy The results of ‘Comparative Effectiveness of Aspirin Dosing in Cardiovascular […]
IAF to present first symposium at the Oriental Congress of Cardiology (OCC)
The International Aspirin Foundation (IAF) will present its first ever symposium in China, at the 2021 Oriental Congress of Cardiology (OCC). The OCC conference, themed ‘Open, creative, co-operative’ will be held at the Shanghai International Convention Centre from 27 to 30 May 2021, and the IAF symposium will take place from 1pm to 5pm on […]
ASCO highlight aspirin’s role in reducing hereditary cancer risk.
The American Society of Clinical Oncology (ASCO), in their 16th Annual Report on Progress Against Cancer – Clinical Cancer Advances 2021, highlight the preventative role of aspirin in reducing cancer risk for people with a hereditary cancer predisposition. The report explains the massively increased cancer risk experienced by those with the hereditary condition Lynch syndrome. […]
Senior Science Award – full report now available
Professors Tom Meade, Jan van Gijn, Bo Norrving and Lars Wallentin, the scientists whose work established low-dose aspirin as a mainstay of antithrombotic therapy in the treatment and prevention of heart attack and stroke. Download the full report here
Polypill plus aspirin prevents primary CVD events in people at medium risk (TIPS-3)
This multicentre, 2-by-2-by-2 factorial study randomised 5713 participants with medium cardiovascular disease (CVD) risk to receive a polypill (containing a statin and three blood pressure medications) or placebo daily, aspirin 75 mg daily or placebo and vitamin D or placebo monthly. The study took place between 2012 and 2017 and participants were followed up for […]
Polypill, including aspirin, is effective in reducing cardiovascular events
The PolyIran study a pragmatic, cluster-randomised trial explored the utility of a fixed-dose polypill strategy for reducing cardiovascular disease (CVD). The polypill contained aspirin 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg and enalapril 5 mg. If participants developed a cough, they were changed to polypill two with valsartan 40mg replacing enalapril 5 mg. The […]
Low-dose aspirin reduces CRC risk by 11% in Taiwan study
Low-dose aspirin reduces CRC risk by 11% in Taiwan study In Taiwan, low-dose aspirin is a prescription only drug used for cardiovascular disease prevention. This makes it easier to study who is taking and not taking the drug along with concordance rates. In this nested case-control study 4, 710 504 eligible individuals were identified from […]
Coronary artery calcium score marker for net benefit of aspirin
2020 November A cohort study of participants from the Dallas Heart Study who were free from atherosclerotic cardiovascular disease and not taking aspirin at baseline were investigated to see the impact of increasing coronary artery calcium (CAC) on both bleeding and atherosclerotic cardiovascular disease (ASCVD) events. Having a higher CAC is a risk factor for […]
Research pioneers celebrated in Senior Science Award ceremony
The international trialists Professors Lars Wallentin, Jan van Gijn, Bo Norrving and Tom Meade were recognised for their work on low-dose aspirin, with the presentation of the International Aspirin Foundation Senior Science Award. The Award, supported by Bayer AG, was presented at a virtual ceremony, during which the recipients gave both historic and up to […]
Aspirin contributes to improved CVD outcomes for people with type 2 diabetes
Aspirin as part of a cardiovascular (CVD) prevention strategy has contributed towards a reduction in the risk of having a myocardial infarction (MI) in people with type 2 diabetes over the last 15 years. This Danish study, presented as a late breaker at the European Society of Cardiologists (ESC), is the first to examine the […]
